Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia

Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib

(2011) M. Breccia et al.   HAEMATOLOGICA

Long-term pattern of pleural effusion from chronic myeloid leukemia patients in second-line dasatinib therapy

(2011) Dongho Kim et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib

(2011) Roberto Latagliata et al.   LEUKEMIA RESEARCH

Extensive pleural and pericardial effusion in chronic myeloid leukemia during treatment with dasatinib at 100 mg or 50 mg daily

(2010) M.-T. Krauth et al.   HAEMATOLOGICA

Clinical features of dasatinib-induced large granular lymphocytosis and pleural effusion

(2010) Yasunobu Nagata et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

(2010) Hagop Kantarjian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dasatinib-Induced Pleural Effusions: A Lymphatic Network Disorder?

(2009) Mark Goldblatt et al.   AMERICAN JOURNAL OF THE MEDICAL SCIENCES

Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion

(2009) Kimmo Porkka et al.   CANCER

The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib

(2009) David Masiello et al.   Journal of Hematology & Oncology

Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors

(2009) Kevin Kelly et al.   Targeted Oncology

Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials

(2008) S. Branford et al.   BLOOD

Intermittent Target Inhibition With Dasatinib 100 mg Once Daily Preserves Efficacy and Improves Tolerability in Imatinib-Resistant and -Intolerant Chronic-Phase Chronic Myeloid Leukemia

(2008) Neil P. Shah et al.   JOURNAL OF CLINICAL ONCOLOGY